Androgens are responsible for the development
of male characteristics by binding to androgen receptors. Androgen receptor
plays an important role in the development and progression of prostate cancer.
Thus, it has been an attractive target for the clinical interventions and treatment
of prostate cancer. This has led to the development of new therapies for the
better treatment of castration-resistant prostate cancer.
Several
studies have demonstrated the promising results of cancer immunotherapy with
androgen receptor antagonists for the treatment of prostate cancer. Androgen
receptor antagonists with immunotherapy enhanced the immune response and
prevent the relapse of advanced prostate cancer. Thus, providing many
opportunities to the companies for the development of combination therapies of
androgen receptor antagonists with immunotherapy for the treatment of prostate
cancer.
Request to Get the Sample Pages at:
Taiho
Pharmaceutical Co. Ltd. is in the process of developing TAS3681 as a novel oral
androgen receptor antagonist with dual mechanism of action, acting as both an
androgen receptor antagonist and a down-regulator of androgen receptor, for the
treatment of prostate cancer. Pfizer Inc., Eisai Co., Ltd., and Evgen Pharma
Limited are some other companies having pipeline of androgen receptor
antagonist.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with detailed analysis of
pipeline and clinical trials. Pipeline analysis of drugs by phases includes
product description and development activities including information about
clinical results, designations, collaborations, licencing, grants, technology
and others.
